Document is current
Any future updates will be listed below
-
Authors
Stögmann, Elisabeth https://orcid.org/0000-0003-4688-8482
Schmidt, Reinhold
-
Funding
Funding for this research was provided by:
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 5 July 2024
Accepted: 3 October 2024
First Online: 6 November 2024
Conflict of interest
: E. Stögmann received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies: Biogen, Roche, Novo Nordisc, Eisai, Novartis, Sanofi and Lilly. She held leadership or a fiduciary role in scientific societies (Austrian Alzheimer Association, the EAN scientific panel dementia). Her institution (Medical University of Vienna, Austria) received financial support for participation in clinical trials from Lundbeck, Biogen, Novo Nordisc and Roche Diagnostics. Her institution (Medical University of Vienna, Austria) received financial support by research grants for research in AD: Roche, Eisai, EU Horizon 2020 and the Austrian Alzheimer Association. R. Schmidt received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies: Biogen, Roche, Eisai, Novartis, Pfizer, Lundbeck , Merz Austria. He held leadership or a fiduciary role in scientific societies (Austrian Alzheimer Association, the EAN scientific panel dementia, VasCog). His institution (Medical University of Graz, Austria) received financial support for participation in clinical trials from Lundbeck, Biogen, Novo Nordisc, Merz Austria, Pfizer, Novartis, Axon Neuroscience, Neuroscios. His institution (Medical University of Graz, Austria) received financial support by research grants for research in AD: Austrian Science Fund, Austrian Research Promotion Agency, National Institute of Health, USA, European Union Joint Programme-Neurodegenerative Disease Research, European Union-Era-Net Neuron and the Austrian Alzheimer Association.
